Onkologie. 2011:5(3):151-154

POEMS syndrome

Jiří Minařík, Vlastimil Ščudla, Jaroslav Bačovský, Tomáš Pika
III. interní klinika FN a LF UP Olomouc

POEMS syndrome is a rare clinical entity with a very variable behaviour and clinical manifestation. It belongs to a group of diseases

known as plasma cell dyscrasias and is characterised by a coincidence of monoclonal gammopathy with peripheral neuropathy and

focal osteosclerotic bone lesions.

Using three case reports, our paper presents different manifestations of this clinical entity as well as an assessment of possible diagnostic

and therapeutic approaches to individuals with POEMS syndrome.

The aim is to present this less known condition from the group of monoclonal gammopathies as well as the practical approach to diagnosing

individuals with concurrent paraprotein and peripheral neuropathy.

Keywords: POEMS syndrome, monoclonal gammopathies, neuropathy, osteosclerotic bone lesions

Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Minařík J, Ščudla V, Bačovský J, Pika T. POEMS syndrome. Onkologie. 2011;5(3):151-154.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dispenzieri A. Diagnosis and treatment of POEMS syndrome. In: Rajkumar SV, Kyle RA, Treatment of multiple myeloma and related disorders. Cambridge university press, New York, NY, USA, 2009: 182-195. Go to original source...
    2. Rajkumar SV, Kyle RA, Suarez GA, et al. Neuropathy associated with plasma cell proliferative disorders. In: Gertz MA, Greipp PR. Multiple myeloma and related plasma cell disorders. Mayo Foundation for medical education and research, Rochester, MN, USA, 2004: 35-52. Go to original source...
    3. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003; 101: 2496-2506. Go to original source... Go to PubMed...
    4. Dispenzieri A. Mayo Clinic Criteria for the Diagnosis of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. Note. From "POEMS Syndrome," Blood Reviews 2007; 21: 287.
    5. Osby E, Noring L, Hast T, et al. Benign monoclonal gammopathy and peripheral neuropathy. Br J Haematol 1982; 51: 531-539. Go to original source... Go to PubMed...
    6. Nobile-Orazio E, Barbieri S, Baldini L, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand 1992; 85: 383-390. Go to original source... Go to PubMed...
    7. Suarez GA, Kelly JJ. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1993; 43: 1304-1308. Go to original source... Go to PubMed...
    8. Vrethem M, Cruz M, We-In H, et al. Clinical neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies J Neurol Sci 1993; 113: 193-199. Go to original source... Go to PubMed...
    9. Fisher MA, Wilson JR. Characterizing Neuropathies Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS): A Framework Consistent With Classifying Injuries According to Fiber Size. Neur Clin Neurophys 2002; 3: 2-6. Go to original source... Go to PubMed...
    10. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy. Cur Opin Neurol 2009; 22: 480-485. Go to original source... Go to PubMed...
    11. Adam Z. Diferenciální diagnostika monoklonálních gamapatií. Intern Med pro Praxi 2004; 6: 279-283.
    12. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995; 37: 32-42. Go to original source... Go to PubMed...
    13. Narvaez JA, Majos C, Narvaez J, et al. POEMS syndrome: unusual radiographic, scintigraphic and CT features. Eur Radiol 1998; 8: 134-136. Go to original source... Go to PubMed...
    14. Ščudla V. Postižení pohybového systému u mnohočetného myelomu. In Rovenský J. A kol. Reumatológia v teórii a praxi. Osveta 2004: 629-631.
    15. Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 2005; 128: 1911-1920. Go to original source... Go to PubMed...
    16. Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996; 347: 702. Go to original source... Go to PubMed...
    17. Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve, 1998; 21: 1390-1397. Go to original source...
    18. Dispenzieri A. POEMS Syndrome. Blood Rev 2007; 21: 285-299. Go to original source... Go to PubMed...
    19. Kuwabara S, Misawa S, Kanai K, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006; 66: 105-107. Go to original source... Go to PubMed...
    20. Giglia F, Chiapparini L, Fariselli L, et al. POEMS syndrome: relapse after autologous peripheral blood stem cell transplantation. Neuromuscular disorders 2007; 17: 980-982. Go to original source... Go to PubMed...
    21. Imai N, Taguchi J, Nobuyasu Y, et al. Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS syndrome) without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation. Neuromuscular Disorders 2009; 19: 363-365. Go to original source... Go to PubMed...
    22. Ohguchi H, Ohba R, Onishi Y, et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome. Ann Hematol 2010, DOI 10.1007/s00277-010-1133-8. Go to original source... Go to PubMed...
    23. Sinisalo M, Hietaharju A, Sauranen J, Wirta O. Thalidomide in POEMS syndrome: case report. Am J Hematol 2004; 76: 66-68. Go to original source... Go to PubMed...
    24. Kaygusuz I, Tezcan H, Cetiner M, et al. Bortezomib: a new therapeutic option for POEMS syndrome. Eur J Hematol 2010; 84: 175-177. Go to original source... Go to PubMed...
    25. Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood 2005; 106: 1135. Go to original source... Go to PubMed...
    26. Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood 2006; 107: 4972-4973. Go to original source... Go to PubMed...
    27. Samaras P, Bauer S, Stenner-Liewen F, et al. Treatment of POEMS syndrome with bevacizumab. Haematologica 2007; 92: 1438-1439. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.